<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30042282</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>09</Month>            <Day>10</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>10</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Print">0385-0684</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>45</Volume>                    <Issue>7</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Jul</Month>                    </PubDate>                </JournalIssue>                <Title>Gan to kagaku ryoho. Cancer &amp; chemotherapy</Title>                <ISOAbbreviation>Gan To Kagaku Ryoho</ISOAbbreviation>            </Journal>            <ArticleTitle>[A Case of Microangiopathic Hemolytic Anemia with Bone Marrow Carcinomatosis from Breast Cancer].</ArticleTitle>            <Pagination>                <MedlinePgn>1105-1107</MedlinePgn>            </Pagination>            <Abstract>                <AbstractText>We report a case of microangiopathic hemolytic anemia(MHA)caused by metastatic breast cancer treated with weekly paclitaxel. A 58-year-old woman was diagnosed with metastatic breast cancer 2 years earlier. She was treated with various chemotherapy regimens and hormonal therapy, before being switched to fulvestrant 3 months earlier. She presented with severe anemia, and was diagnosed with MHA with bone marrow carcinomatosis following bone marrow biopsy. She was treated with weekly paclitaxel and recovered successfully. A subsequent biopsy showed that the bone marrow carcinomatosis had decreased. MHA due to breast cancer is rare and is associated with poor prognosis; however, rapid initiation of chemotherapy may be effective.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Murakami</LastName>                    <ForeName>Akari</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Breast Center, Ehime University Hospital.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kamei</LastName>                    <ForeName>Yoshiaki</ForeName>                    <Initials>Y</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Kusakabe</LastName>                    <ForeName>Erina</ForeName>                    <Initials>E</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Yamasawa</LastName>                    <ForeName>Haruna</ForeName>                    <Initials>H</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Aoki</LastName>                    <ForeName>Reina</ForeName>                    <Initials>R</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Komatsu</LastName>                    <ForeName>Saaya</ForeName>                    <Initials>S</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Taguchi</LastName>                    <ForeName>Kana</ForeName>                    <Initials>K</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Nishiyama</LastName>                    <ForeName>Kanako</ForeName>                    <Initials>K</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Yamashita</LastName>                    <ForeName>Michiko</ForeName>                    <Initials>M</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Sugimori</LastName>                    <ForeName>Wakana</ForeName>                    <Initials>W</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Asai</LastName>                    <ForeName>Hiroaki</ForeName>                    <Initials>H</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Mizuno</LastName>                    <ForeName>Yosuke</ForeName>                    <Initials>Y</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Takada</LastName>                    <ForeName>Yasutsugu</ForeName>                    <Initials>Y</Initials>                </Author>            </AuthorList>            <Language>jpn</Language>            <PublicationTypeList>                <PublicationType UI="D002363">Case Reports</PublicationType>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>Japan</Country>            <MedlineTA>Gan To Kagaku Ryoho</MedlineTA>            <NlmUniqueID>7810034</NlmUniqueID>            <ISSNLinking>0385-0684</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>P88XT4IS4D</RegistryNumber>                <NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000743" MajorTopicYN="N">Anemia, Hemolytic</DescriptorName>                <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000972" MajorTopicYN="N">Antineoplastic Agents, Phytogenic</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019046" MajorTopicYN="N">Bone Marrow Neoplasms</DescriptorName>                <QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName>                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>                <QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002277" MajorTopicYN="N">Carcinoma</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>                <QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>        </MeshHeadingList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>7</Month>                <Day>26</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>7</Month>                <Day>26</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30042282</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>